Eli Lilly's Diabetes Drug Tirzepatide, Marketed as Mounjaro and Zepbound, Approved in China

May 21, 2024, 08:25 AM

Eli Lilly's diabetes drug tirzepatide has received approval from Chinese regulators, setting the stage for increased competition with Danish rival Novo Nordisk in the key Asian market. The drug, marketed as Mounjaro and Zepbound, is expected to intensify the rivalry over weight-loss drugs in China, the world's second-largest market. However, Eli Lilly has not disclosed when sales will begin in China or the number of doses to be supplied.